TABLE 1.

Characteristics of trials included in the meta-analysis¹

										SBP, mm Hg		DBP, mm Hg
Study (ref)	Year	Country	Preclinical or chronic condition	Duration	Group	Magnesium-supplementation regimen per day	n	Age at baseline, y	Sex, M/F, n	Baseline	End of the study	Baseline	End of the study
Rodríguez-Morán and Guerrero-Romero (18)	2014	Mexico	Insulin resistance	4 mo	Treatment	30 mL MgCl2 5% solution (equivalent to 383 mg elemental Mg)	24	31.92	NA	111.3 ± 14.5	109.4 ± 12.4	71.5 ± 6.6	68.8 ± 7.4
					Placebo	30 mL placebo	23	39.52	NA	109.4 ± 12.4	116.6 ± 11.5	71.4 ± 9.3	76.8 ± 7.6
Simental-Mendía et al. (19)	2014	Mexico	Prediabetes	12 wk	Treatment	30 mL MgCl2 5% solution (equivalent to 383 mg elemental Mg)	29	39.8 ± 163	16/13	114.8 ± 31.1	117.5 ± 18.6	76.9 ± 12.9	75 ± 14.5
					Placebo	30 mL NaHCO3 0.1% solution	28	41.1 ± 13.1	17/11	115.7 ± 21.4	123.4 ± 22.2	73.2 ± 10.5	76.9 ± 10.8
Simental-Mendía et al. (25)	2012	Mexico	Prediabetes	12 wk	Treatment	30 mL MgCl2 5% solution (equivalent to 383 mg elemental Mg)	11	44.2 ± 10.8	4/7	116.9 ± 7.6	115.5 ± 18	66.7 ± 6.9	65.6 ± 10.4
					Placebo	30 mL NaHCO3 0.1% solution	11	43.2 ± 7.8	4/7	118.4 ± 8.2	114 ± 9.7	71.8 ± 7.5	66.6 ± 8.7
Mooren et al. (16)	2011	Germany	Insulin resistance	6 mo	Treatment	Verum (magnesium aspartate hydrochloride), 365 mg Mg	25	NA	NA	137.7 ± 14.9	131.4 ± 16.4	85.3 ± 9.4	81.6 ± 9.8
					Placebo	Not specified	22	NA	NA	134.8 ± 15	133.1 ± 21.9	82.5 ± 9.6	83.2 ± 12.1
Barbagallo et al. (14)	2010	Italy	Type 2 diabetes	1 mo	Treatment	4.5 g Mg pidolate (equivalent to 368 mg Mg ion)	30	71.0 ± 4.9	18/12	150 ± 7	148 ± 5	82 ± 5	79 ± 5
					Placebo	No placebo was used in the control	30	71.2 ± 4.6	17/13	148 ± 8	147 ± 6.5	83 ± 5	82 ± 5
Guerrero-Romero and Rodríguez-Morán (13)	2009	Mexico	Type 2 diabetes	4 mo	Treatment	2.5 g MgCl2 (equivalent to 450 mg elemental Mg)	40	58.9 ± 8.5	19/21	161.1 ± 26	140.7 ± 11.9	88.4 ± 14.5	79.7 ± 7.1
					Placebo	Inert placebo	39	60.5 ± 9.4	19/20	154.5 ± 21.2	149.8 ± 20.6	84.9 ± 12.4	83.8 ± 9.7
Barragán-Rodríguez et al. (23)	2008	Mexico	Type 2 diabetes	12 wk	Treatment	50 mL MgCl2 5% solution (equivalent to 450 mg elemental Mg)	12	69 ± 5.9	NA	134.1 ± 19.2	135.2 ± 20.5	77.2 ± 3.1	77 ± 3.6
					Placebo	Imipramine 50 mg	9	66.4 ± 6.1	NA	141.0 ± 20.1	143.7 ± 19.9	84.7 ± 6.1	87.6 ± 6.4
Guerrero-Romero et al. (20)	2004	Mexico	Type 2 diabetes	12 wk	Treatment	2.5 g MgCl2 (equivalent to 450 mg elemental Mg)	32	43.0 ± 7.9	NA	110 ± 8.4	108 ± 8.1	73 ± 7.5	72.3 ± 7.4
					Placebo	Not specified	31	42.2 ± 6.8	NA	111 ± 12	110 ± 11	73 ± 9	72.4 ± 8.9
Rodríguez-Morán and Guerrero-Romero (17)	2003	Mexico	Insulin resistance	16 wk	Treatment	2.5 g MgCl2 (equivalent to 450 mg elemental Mg)	32	59.7 ± 8.3	NA	148.2 ± 32.3	140.2 ± 28.1	86.3 ± 17	82.7 ± 16.4
					Placebo	Not specified	31	54.1 ± 9.6	NA	138.1 ± 25.6	135 ± 19.6	80.5 ± 14.6	79.1 ± 13.5
Shechter et al. (24)	2000	United States	Coronary artery disease	6 mo	Treatment	Magnesium product4 containing 365 mg total Mg (equivalent to 200 mg elemental Mg 2 times/d)	25	68 ± 10	21/3	147 ± 21	143 ± 20	69 ± 10	69 ± 10
					Placebo	Not specified	25	66 ± 12	19/6	145 ± 18	140 ± 19	69 ± 14	68 ± 7
de Valk et al. (15)	1998	Netherlands	Type 2 diabetes	3 mo	Treatment	15 mmol Mg aspartate HCl (365 mg Mg)	18	63.0 ± 8.2	12/6	162.6 ± 23.3	158.7 ± 20	84 ± 11.5	82.9 ± 8.3
					Placebo	Not specified	16	62.0 ± 7.3	8/8	157.4 ± 23.6	146.9 ± 21.8	83 ± 14.2	77.1 ± 8.4

¹DBP, diastolic blood pressure; NA, not available; ref, reference; SBP, systolic blood pressure.

²Mean.

³Mean ± SD (all such values).

⁴Magnosolv-Granulat (Meda).